Childhood Spinal Cord Neoplasm Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0030212 (Childhood Spinal Cord Neoplasm)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00381797Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade GliomaTreatment